TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05482880

Intervention type: OTHER
Intervention: Regular care with additionally administration of questionnaires
Description: Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points:~1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone.~2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone.~Completing the questionnaires takes about 30 minutes each time.~\*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital.
Study: NCT05072535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HA121-28 tablet A
Description: HA121-28 tablet A 200 mg
Study: NCT05983302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repairing Gel
Description: The second intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repairing Gel and Platelet-Rich Plasma-Fibrin Glue
Description: The third intervention group includes 10 patients with chronic wounds who, despite common treatment, will be undergone the repairing gel with approved wound healing components in the form of gel and PRP-FG for 8 weeks.
Study: NCT05233722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 1 hour of one-legged knee-extensor exercise followed by 4 hours of rest

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: 1 hour of one-legged knee-extensor exercise followed by 4 hours of rest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin infusion
Description: 2 hours of Euglycemic Hyperinsulinemic Clamp

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Insulin infusion
Description: 2 hours of Euglycemic Hyperinsulinemic Clamp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of 800 mg of calcium tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Administration of 16 mg of Rapamycin tablets
Study: NCT06197243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Patients will receive acupuncture for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Patients will receive yoga therapy with one of three yoga instructors. Patients will remain with singular yoga instructor for duration of study. It is anticipated that patients will participate in yoga therapy for 12 weeks at home and in-clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deprescribing
Description: Deprescribing of patients' benzodiazepine use will be monitored by psychiatric nurse. Tapering method will be followed for medication deprescription.
Study: NCT05244876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back school
Description: Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
Study: NCT05290896

Intervention type: DEVICE
Group type: OTHER
Intervention: Phacoemulsification
Description: Phacoemulsification for senile cataract.
Study: NCT04154488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavorixafor
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Study: NCT05983302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical wound irrigation (control)
Description: For 10 patients with chronic wounds, only the classical wound irrigation by normal saline will be continued for 8 weeks.
Study: NCT06202989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiprofen-CC™ plus standard treatment
Description: Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus standard treatment
Description: The placebo is the base cream with no medicinal ingredients to be applied 3 times per day for 6 weeks after surgery
Study: NCT06343883

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - low pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - low pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - medium pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - medium pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - high pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - high pressure
Description: low-intensity focused ultrasound applied to the S1.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity focused ultrasound - high pressure
Description: low-intensity focused ultrasound applied to the S1.
Study: NCT05971888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food system and demand generation
Description: GAIN's program to increase dairy consumption among BoP children and workers will include components to increase demand, improve access, and support the enabling environment. In Amhara, the demand generation component will share messages through radio, community influencers, and community conversations led by health extension workers targeting rural BoP households with children 6 months up to 7 years. GAIN will train milk houses and cooperatives on dairy safety and quality assurance and better business practices and will assist with cold chain and milk dispensing technology to improve milk availability and access. In industries and large-scale farms, GAIN will use a demand generation strategy to inform workers about the importance of dairy products and other nutritious foods and to encourage them to purchase them at their workplaces. GAIN will work with local businesses to launch and maintain dairy dispensers and arrange provision of other nutritious foods at work sites.
Study: NCT05032599

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD5 CART
Description: Subjects will be pretreated with chemotherapy prior to infusion of CAR T cells: After the collection of PBMC and about 5 days before infusion, lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 250 mg/m\^2/day; for prior-SCT donor-derived CAR T-cell infusion) or intensified lymphodepletion (fludarabine at 30 mg/m\^2/day and cyclophosphamide at 30 mg/kg/day; for new donor-derived CAR T-cell infusion) will be administrated for 3 days.
Study: NCT06032598

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract 1
Description: The study foresees the intake of 1 capsule per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry extract 2
Description: The study foresees the intake of 1 capsule per day during 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study foresees the intake of 1 capsule per day during 84 days
Study: NCT05058638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aquamin
Description: Participants will take a 90-day supply of Aquamin®, 4 capsules per day; 2 to be taken in the morning and 2 in the evening (containing approximately 800 mg calcium/day).
Study: NCT06531473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP
Description: Patients will be randomized to one of the laser energy groups day of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP
Description: Patients will be randomized to one of the laser energy groups day of surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HoLEP
Description: Patients will be randomized to one of the laser energy groups day of surgery.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study: NCT05017948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk score based intervention
Description: Targeted interventions based off of risk score software
Study: NCT05181631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biobanking
Description: Collection of blood (One tube of blood 4-5 ml + One EDTA tube of blood 5 ml) will be attempted for each participant at baseline. Availability of these samples will be indicated in the e-CRF.~Samples will be collected by hospital staff and stored following regulatory conditions of conservation in CRB of Hospital Avicenne under the responsibility of Pr Marianne ZIOL.
Study: NCT03654079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation
Description: Participants assigned to the intervention group will participate in the following simulations: 1) the process that may occur if a baby has a significant drop in heart rate during labor, 2) the process of moving from the labor bed to the transport stretcher and on to the operating room in the event that a woman needs a cesarean delivery, 3) the pushing process after a woman becomes completely dilated
Study: NCT05100017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methocarbamol
Description: Patients will receive oral Methocarbamol 750mg every six hours as needed for pain post ureteroscopy in addition to the standard postoperative pain regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: Patients will receive oral Oxybutynin XL 10mg daily for pain post ureteroscopy in addition to the standard postoperative pain regimen.
Study: NCT05180773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: Bromocriptine 2.5 mg one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects not on anticoagulation at the time of entry will also receive rivaroxaban 10 mg tablets once daily for 8 weeks while on bromocriptine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one tablet by mouth twice daily for 2 weeks then once daily for 6 weeks. Subjects who are not on anticoagulation will not receive rivaroxaban but will receive a second placebo once daily for 8 weeks while on study drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Guideline Directed Medical Therapy for Heart Failure (GDMT)
Description: GDMT will potentially include angiotensin converting enzyme inhibitors (ACEi), angiotensin II receptor antagonists (ARB), angiotensin receptor blocker-neprilysin inhibitors (ARNI), beta adrenergic receptor antagonists (beta blockers) , Mineralocorticoid receptor antagonists (MRA), sodium-glucose cotransporter-2 inhibitors (SGLT2i),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Subjects not on anticoagulation clinically who are randomized to bromocriptine will receive rivaroxaban 10 mg tablets once tablet by mouth daily for 8 weeks while on bromocriptine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Second Placebo
Description: Subjects not on anticoagulation clinically who are randomized to placebo (rather than bromocriptine) will receive a second placebo one tablet by mouth daily for 8 weeks.
Study: NCT04914416

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Verum T17
Description: Verum T17 is a placebo: microcristalline cellulose. Daily dosage is 1000 mg in 3 capsules.
Study: NCT04260243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental-Myofascial + Respiratory rehabilitation
Description: 6 sessions of: Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Myofascial + Respiratory rehabilitation
Description: 6 sessions of: Sham Myofascial Release (20 minutes each) + Respiratory rehabilitation (60 minutes each)
Study: NCT06132581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic delta-beta coupling in the brain.
Study: NCT06219707

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture needles
Description: The acupuncture needles and related equipment will have already received approval for routine Traditional Chinese Medicine (TCM) clinical practice in Singapore.
Study: NCT06298864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-CBT
Description: * Common reactions following ACS. The role of cardiac anxiety and avoidance behavior on quality of life and physical health. Brief training in self-observation, i.e., labeling. General lifestyle advice on e.g., physical activity, diet.~* Identifying life areas impaired by ACS-related disability or symptom fear. Set health behavioral goals i.e., increased physical activity and gradually take steps towards them.~* Gradual exposure to physical sensations (e.g., palpitations due to physical activity) to reduce fear of these symptoms.~* Gradual exposure to avoided situations, activities and increase in physical activity.~* Prevention of relapse into avoidance behaviors by identifying risk situations and conduct a plan forward on maintaining a healthy physically and active lifestyle.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-CL
Description: * Education on ACS, risk factors, its treatments and medication.~* Education and advice promoting healthy habits regarding diet, alcohol and tobacco.~* Education and advice regarding physical activity and the beneficial effects on health.~* Education regarding common emotional reactions following ACS.~* Prevention of relapse and plan forward to maintain a healthy lifestyle.
Study: NCT06132581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform for stimulation was designed to mimic theta-gamma coupling in the brain and is used as an active comparator.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Description: Stimulation will be delivered via the Neurocare Direct Current Stimulator Multi-Channel 4, an investigational electrical non-invasive brain stimulation device that is being used for foundational neuroscience and translational research. The electrical waveform is randomly selected to be the theta-gamma or delta-beta waveform, but the stimulation is delivered for only a brief period of time of approximately 30 seconds, which is not sufficient to produce a meaningful dose to the brain. This placebo, or sham, stimulation is designed to mimic the sensation of receiving stimulation.
Study: NCT04946227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Description: Pembrolizumab 200mg +Paclitaxel 80mg/m2
Study: NCT05144451

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler
Description: Transcranial Doppler-derived parameters; pulsatility index (PI), resistance index (RI), mean flow velocity (Vmean) will be recorded before induction of anesthesia (T1).~After induction, TCD parameters, Hemodynamic variables including heart rate (HR), invasive mean arterial blood pressure (MAP), and central venous pressure (CVP) together with Arterial blood gases (ABG analysis with values of PH, PCO2, PO2, blood oxygen saturation SO2 and bicarbonate HCO3), end-tidal carbon dioxide (ETCO2) and body temperature will be recorded too. Just before skin incision (T2), at the end of anhepatic phase 5 minutes before reperfusion (T3), 5 minutes after reperfusion (T4) and at the end of surgery (T5).~Postoperatively at ICU, TCD parameters, Hemodynamic variables, and ABG will be obtained 24 hours postoperative (T6) and at discharge from ICU (T7).
Study: NCT03914664

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram (EEG) testing procedure
Description: EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG

Intervention type: DIAGNOSTIC_TEST
Intervention: Electroencephalogram (EEG) testing procedure
Description: EEG testing procedure, comprised of somatosensory and auditory event-related potential paradigms, as well as resting state EEG

Intervention type: DIAGNOSTIC_TEST
Intervention: Autonomic function testing procedure
Description: Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)

Intervention type: DIAGNOSTIC_TEST
Intervention: Autonomic function testing procedure
Description: Autonomic function testing procedure, comprised of electrodes to determine heart rate variability and electrodermal activity (EDA)
Study: NCT05597631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G-IVF PLUS
Description: Experimental
Study: NCT05651958

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nebulizer
Description: Active Comparator: Nebulization every 3 days with the other medicine to the active comparator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Technique
Description: 15 repeatations of Breathing in morning and evening
Study: NCT06363799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4th ventricle compression technique
Description: For the CV4 the mediator's hands assume a specific position: one on top of the other, with the tips of the thumbs joined together in a V shape, positioned approximately on the process spinous between the patient's second and third cervical vertebrae, pointing downwards.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Technique
Description: The participant is instructed to lie down in the supine position while the mediator assumes a position at the head of the table and places their hands on the participant's shoulders. This technique is performed for 5 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing technique
Description: For the diaphragmatic breathing the participant will place one hand on their chest and the other over their abdomen. Both of their hands will be overlapped by the mediator's, so it is easier to feel the correct breathing movements to be performed.
Study: NCT05404490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 20 mL of bupivacaine 0.5% will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL of Normal Saline Solution will be infiltrated. 10 mL will be infiltrated in the inferior border and 10 mL in the superior border of the subcutaneous cellular tissue.
Study: NCT04298216

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Analysis of Inferior Vena Cavae (IVC)
Description: Novel Operators will attempt to visualize the Inferior Vena Cavae through two different views on the patient's body. The images taken will be interpreted by an expert ultrasound user to determine if the novel operator was successful in locating and evaluating the IVC.
Study: NCT05965713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurolutions IpsiHand System
Description: The IpsiHand system utilizes a Brain-Computer Interface (BCI) to enable operation of a robotic hand exoskeleton worn on the hand and wrist as participants are guided through a rehabilitation program on a tablet. Participants will complete 12 weeks of home therapy with the IpsiHand system. Motor function of their impaired upper extremity will be evaluated at baseline, at 4-week intervals, and 12 weeks completion of IpsiHand use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care - Home Exercise Program for Upper Extremity
Description: Subjects will receive a customized home range of motion exercise program. Subjects will be recommended to complete their exercises daily, 5 out of 7 days per week for 12 weeks